Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

NEXT STORY
Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million
PREV STORY
Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote

Stockholm, December 24, 2018. PledPharma AB (publ) announces that the company has filed an ...

author_avatar
NASDAQ Market News

Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference

VANCOUVER, British Columbia, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...

author_avatar
NASDAQ Market News

Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine

Phase 2 trial of NanoFlu vaccine expected to begin in third quarter of 2018Given ...

author_avatar
NASDAQ Market News